Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Free Report) Director David Scott Moore bought 21,700 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was bought at an average cost of $11.53 per share, for a total transaction of $250,201.00. Following the completion of the purchase, the director owned 21,700 shares of the company’s stock, valued at approximately $250,201. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.
Corvus Pharmaceuticals Price Performance
Shares of Corvus Pharmaceuticals stock traded down $0.03 during trading on Monday, hitting $11.90. 704,413 shares of the company’s stock traded hands, compared to its average volume of 2,549,292. Corvus Pharmaceuticals, Inc. has a 1 year low of $3.55 and a 1 year high of $26.95. The stock has a market capitalization of $1.00 billion, a P/E ratio of -22.88 and a beta of 0.84. The business has a 50-day simple moving average of $14.00 and a 200-day simple moving average of $13.69.
Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). On average, equities analysts predict that Corvus Pharmaceuticals, Inc. will post -0.7 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analyst Ratings Changes
Several equities research analysts recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Corvus Pharmaceuticals in a research report on Friday, March 13th. Wall Street Zen cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. The Goldman Sachs Group started coverage on shares of Corvus Pharmaceuticals in a research report on Friday, April 17th. They set a “buy” rating and a $40.00 target price for the company. Oppenheimer reiterated an “outperform” rating and issued a $33.00 price target (up from $32.00) on shares of Corvus Pharmaceuticals in a research report on Friday, March 13th. Finally, Weiss Ratings upgraded shares of Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 29th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $33.33.
Get Our Latest Stock Report on CRVS
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.
Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.
Read More
- Five stocks we like better than Corvus Pharmaceuticals
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
